Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference on March 15, 2022, at 8:00 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference on March 15, 2022, at 8:00 AM ET. The management team will engage in a fireside chat, which will be webcast live. An archived recording will be available post-event on their website. Madrigal focuses on innovative therapeutics for non-alcoholic steatohepatitis (NASH) and leads with resmetirom, currently in Phase 3 studies.
Details
News Market Reaction – MDGL
The recorded move for MDGL in the trading session of this news was +0.71%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in the 32nd Annual Oppenheimer Healthcare Conference on Tuesday, March 15, 2022 at 8:00 AM ET.
The fireside chat presentation will be webcast live and an archived recording will be available for replay in the Investors & Media section of the Madrigal website after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com.
Investor Contact
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com
Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.